Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been recently diagnosed with a specific type of blood cancer called B-cell acute lymphoblastic leukemia (a type that tests negative for a marker called "Philadelphia chromosome"), confirmed using standard diagnostic guidelines
- Your cancer cells test positive for a protein called CD22 on their surface
- You are 18 years of age or older
- Your doctor estimates you are likely to survive for at least 3 months
- If you are able to have children (male or female), you agree to use effective birth control during the study
- You are willing and able to understand, sign the consent forms, and follow all the requirements of the study
Who may not be able to join:
- You have a specific type of cancer called Burkitt lymphoma or Burkitt leukemia
- Your leukemia cannot be clearly classified as one specific type (known as "ambiguous lineage" leukemia)
- You are currently pregnant
- You have a serious, uncontrolled active infection
- You have a history of long-term liver disease (such as cirrhosis) or a condition involving blockage of blood vessels in the liver
- You have a history of serious heart rhythm problems, unexplained fainting, or certain types of heart conduction issues, or a persistently slow heart rate (unless you have a permanent pacemaker)
- You currently have or have had hepatitis B, hepatitis C, or HIV infection
- You have a mental health condition that might make it difficult to complete the treatment or give informed consent
- You have any other condition that the trial doctor feels makes you unsuitable for the study (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jianxiang Wang, Institute of Hematology & Blood Diseases Hospital, China
Phone: +862223909120
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
MRD-negative complete remission rate measured by flow cytometry.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.